EVONCABTAGENE PAZURGEDLEUCEL
UNII AZS2UCV4V3

Substance Identification & Data

This profile provides standardized clinical and technical data for Evoncabtagene Pazurgedleucel, uniquely identified by the FDA Unique Ingredient Identifier (UNII) AZS2UCV4V3.

Technical mappings include the Chemical Abstracts Service (CAS) Registry Number N/A and the RxNorm Concept ID (RxCUI) N/A. Explore the sections below for detailed nomenclature and a complete directory of NDC-listed products containing this ingredient.

FDA UNII Code

AZS2UCV4V3

CAS Registry Number

N/A

RxNorm Concept ID

N/A

Detailed Substance Profile

Preferred Name

EVONCABTAGENE PAZURGEDLEUCEL

Official standardized name for this substance within the FDA UNII nomenclature system.

NCI Thesaurus

C203124

National Cancer Institute reference terminology for clinical and research data.

INN ID

11599

Sequential identifier assigned via the WHO International Nonproprietary Name program.

Substance Type

Evoncabtagene Pazurgedleucel

ISO 11238 classification category (e.g., Chemical, Polymer, Protein).

ITIS TSN

180092

Taxonomic Serial Number for species identified in the Integrated Taxonomic Information System.

NCBI Taxonomy

9606

Unique numeric identifier used to specify biological species in the NCBI database.

Synonyms and Nomenclature

This section provides a complete list of nomenclature and identifier mappings for Evoncabtagene Pazurgedleucel. Identifiers are organized into official regulatory terms, commercial trade names, and technical systematic synonyms used to ensure accurate identification across clinical pharmaceutical databases, regulatory filings, and electronic health records.

FDA Official Name

Evoncabtagene Pazurgedleucel

Common Names & Synonyms

allogeneic T cells obtained from peripheral blood by leukapheresis, genetically modified by CRISPR/Cas9 (clustered regularly interspaced short palindromic repeats/CRISPR-associated protein 9) mediated gene editing consisting of two guide RNAs (gRNAs) introduced transiently as CAS9-gRNA ribonucleoprotein (RNP) complex for the targeted disruption of the T cell receptor alpha chain constant (TRAC) and β2 microglobulin (B2M) loci and insertion of an anti-CD19 chimeric antigen receptor (CAR) transgene into the TRAC locus via an adeno-associated virus serotype 6 (AAV6) vector. The CAR is composed of a humanized single-chain variable fragment (scFv) derived from the murine antibody FMC63 targeting CD19, followed by a CD8 hinge and transmembrane region, a CD28 co-stimulatory domain and a CD3ζ signalling domain. Expression of the CAR is driven by the elongation factor 1 alpha (EF-1α) promoter and is terminated by a synthetic polyadenylation sequence. The CD19 expression cassette is flanked by two TRAC homology arms guiding the expression cassette to the TRAC locus. The T cells are cultured in the presence of growth medium containing interleukin 2 (IL-2) and 7 (IL-7) and are ≥30% CAR+ T cells, ≤0.5% TCR+ and ≤30% B2M+

evoncabtagene pazurgedleucel [INN]

Technical Codes

CTX-110

External Clinical & Regulatory Resources

Previous UNIIAZR7U6K4HC

Next UNIIAZS375HVG8